Clinical trials: Pancreatic Cancer Stage III
Pancreatic Cancer
Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002689
- Testing
- dexamethasone, fluorouracil, brachytherapy
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Center for Molecular Medicine
Cachexia, Pancreatic Cancer
Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss
RATIONALE: Learning about biological markers in patients with pancreatic cancer and cachexia may help doctors predict patient outcome and may help the study of cancer in the future.
- Trial name
- NCT00899158
- Testing
- immunologic technique, laboratory biomarker analysis, biopsy
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Neoplasms, Urogenital Neoplasm
The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery
To study if plasma volume expansion is influenced by the rate at which a colloidal solution is administered in patients with a systemic inflammatory response induced by major abdominal surgery.
- Conditions
- Pancreatic Neoplasms, Urogenital Neoplasm, Systemic Inflammatory Response Syndrome, Hypovolemia
- Trial name
- AIR (NCT02728921)
- Testing
- 5% Albumin infusion 30 min, 5% Albumin infusion 3 hours
- Where
- Sweden
- Volunteers
- 70 people
- Sponsor
- Region Skane
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease.
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
- Trial name
- PILLAR (NCT01836432)
- Testing
- FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation
- Where
- 32 sites in United States
- Volunteers
- 302 people
- Sponsor
- NewLink Genetics Corporation
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma
- Trial name
- NCT01010126
- Testing
- Bevacizumab, Temsirolimus
- Where
- 61 sites in United States, Canada
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT01131234
- Testing
- Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of tumor cells.
- Trial name
- NCT00059826
- Testing
- interferon-alfa-2b, cisplatin, 5-fluorouracil
- Where
- 14 sites in United States
- Volunteers
- 89 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112658
- Testing
- fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- 55 sites in France
- Volunteers
- 342 people
- Sponsor
- UNICANCER
Pancreatic Cancer
Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
RATIONALE: Perifosine may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced…
- Trial name
- NCT00059982
- Testing
- perifosine
- Where
- 10 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first…
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT04514497
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 23 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Pancreatic Cancer, Pancreatic Adenocarcinoma Non-resectable
Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer
This clinical trial compares the effect of malnutrition screening and dietary intervention to standard nutrition care on patients with pancreatic cancer that cannot be removed by surgery (unresectable).
- Trial name
- NCT06090916
- Testing
- Best Practice, Dietary Intervention, Medical Chart Review
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Pancreas Cancer
NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer
The aim of this study is to test the additional value of neoadjuvant chemotherapy to the standard treatment for resectable pancreatic cancer (surgery + adjuvant chemotherapy).
- Trial name
- NEOPAC (NCT01521702)
- Testing
- Neoadjuvant chemotherapy, surgery and Adjuvant chemotherapy
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Institut Paoli-Calmettes
Pancreatic Cancer
Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Opioid growth factor may stop the growth of pancreatic cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well opioid growth factor works in treating patients with advanced…
- Trial name
- OGF (NCT00109941)
- Testing
- opioid growth factor, metenkephalin, OGF-opioid growth factor
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Pancreatic Cancer
ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have advanced cancer…
- Trial name
- NCT00005594
- Testing
- ISIS 2503
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Alabama at Birmingham
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 when given together with gemcitabine hydrochloride in treating patients with advanced solid tumors.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01145456
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, gemcitabine hydrochloride, pharmacological study
- Where
- 2 sites in Canada
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00075452
- Testing
- gemcitabine hydrochloride, oxaliplatin
- Where
- 38 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreatic Cancer
Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003216
- Testing
- fluorouracil, gemcitabine hydrochloride, radiation therapy
- Where
- 107 sites in United States, Canada
- Volunteers
- 518 people
- Sponsor
- Radiation Therapy Oncology Group
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Pancreatic Cancer
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003426
- Testing
- gemcitabine hydrochloride, radiation therapy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT01025882
- Testing
- gemcitabine hydrochloride, stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center